Women's tour mandates gene test for eligibility

July 19 : Tennis players will be required to clear a one-time gene test to compete on the women's tour, the WTA said after updating its eligibility policy on Sunday.

The WTA said the once-in-a-lifetime test for the SRY gene, which helps in determining biological sex, can be conducted via a cheek swab or blood test, with the new policy coming into effect on Tuesday.

The previous WTA policy permitted transgender women to participate if they declared their gender as female and then maintained a lowered testosterone level for a period of two years before competing.

There are no known transgender women currently active at any level of professional tennis.

"Eligibility to participate in WTA tournaments will be confirmed through a required, one-time screening process for the SRY gene," a WTA spokesperson told Reuters.

"Player screening will begin in 2026, following all appropriate confidentiality and data privacy safeguards and concurrent with a comprehensive player engagement program.

"The WTA recognizes that this is a sensitive and complex issue and is committed to treating all players with dignity and implementing the policy in a respectful and thoughtful way.”

Transgender player Renee Richards competed on the women's professional tour from 1977 to 1981 before coaching tennis great and gay rights trailblazer Martina Navratilova.

Navratilova, an 18-time Grand Slam singles champion, has been an outspoken critic of the inclusion of transgender athletes, while world number one Aryna Sabalenka last year said it would be unfair for women to face transgender players.

Others, such as Billie Jean King — the 12-time Grand Slam singles champion who won the original "battle of the sexes" in 1973 — see transgender exclusion as discrimination.

Seve